|
||||||||||||||||||||||
|
|
Alternate Title Phase I Randomized Study of Topical Myristyl Nicotinate Cream on The Skin of Healthy Volunteers
Trial Description Chemoprevention is the use of certain drugs to keep cancer from forming. The use of topical myristyl nicotinate cream may stop skin cancer from forming. This randomized phase I trial is studying the side effects and best way to give topical myristyl nicotinate cream on the skin of healthy volunteers. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Participants will be randomly assigned to one of two treatment groups. Participants in both groups will apply topical myristyl nicotinate to one forearm and a topical placebo to the other forearm once a day for 4 weeks. Participants in group one will apply the drug and placebo to the opposite arms as those in group two. All participants will also undergo blood sample collection for laboratory studies at the beginning of the study and at 2 and 4 weeks. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations Arizona Cancer Center at University of Arizona Health Sciences Center
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |